David Phillips appointed Deputy Chair
BRISBANE, 26 September 2025
QBiotics Group Limited (QBiotics) is pleased to announce that David Phillips has been appointed Deputy Chair.
David has served as a Non-Executive Director of QBiotics since 20 May 2024, contributing deep expertise and guidance to the company’s strategy and governance. David is the chair of the Remuneration Committee.
QBiotics’ Non-Executive Chair, Mark Fladrich commented, “David has played an important role in supporting QBiotics' journey to date. On behalf of the Board, I extend our congratulations to David on his new role and look forward to his continued contribution to QBiotics.”
—ends—
FURTHER INFORMATION STEPHEN DOYLE, CEO & MANAGING DIRECTOR
or
MEDIA ENQUIRIES JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
NOTES FOR EDITORS
ABOUT QBIOTICS
QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need.
Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.
QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.
A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®.
Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.
For more, head to: QBiotics.com or LinkedIn